← All verdicts
Verdict

Overvalued

Every analyzed stock in Overvalued234 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Overvalued" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

ABBV
AbbVie Inc.
Overvalued
Healthcare Risk 51 · Elevated
Price$263.04
Model IV$208.02
P/IV1.24
Premium +26% Return to IV: -20.9%
Market implies +6.9%/yr vs model +4.5% · in line
ABM
ABM INDUSTRIES INC /DE/
Overvalued
Technology Risk 39 · Moderate
Price$49.91
Model IV$39.38
P/IV1.28
Premium +27% Return to IV: -21.1%
Market implies +11.1%/yr vs model +9.8% · in line
ACNB
ACNB CORP
Overvalued
Financial Services Risk 57 · Elevated
Price$65.19
Model IV$46.70
P/IV1.16
Premium +40% Return to IV: -28.4%
AESI
Atlas Energy Solutions Inc.
Overvalued
Energy Risk 58 · Elevated
Price$14.16
Model IV$13.72
P/IV1.22
Premium +3% Return to IV: -3.1%
Market implies +6.8%/yr vs model +8.0% · in line
AIZ
ASSURANT, INC.
Deeply overvalued
Financial Services Risk 69 · High
Price$286.11
Model IV$206.22
P/IV1.21
Premium +39% Return to IV: -27.9%
AKR
ACADIA REALTY TRUST
Overvalued
Financial Services Risk 67 · High
Price$19.77
Model IV$18.12
P/IV1.22
Premium +9% Return to IV: -8.3%
ALDF
Aldel Financial II Inc.
Overvalued
Financial Services Risk 48 · Elevated
Price$10.82
Model IV$8.80
P/IV1.21
Premium +23% Return to IV: -18.7%
Market implies +8.1%/yr vs model +8.0% · in line
AMPG
AmpliTech Group, Inc.
Fairly valued
Technology Risk 49 · Elevated
Price$3.38
Model IV$3.66
P/IV1.21
Discount 8% Return to IV: +8.1%
Market implies +3.7%/yr vs model +47.8% · below model
AMWL
American Well Corp
Deeply overvalued
Technology Risk 40 · Elevated
Price$13.87
Model IV$8.54
P/IV1.15
Premium +62% Return to IV: -38.4%
Market implies +6.4%/yr vs model +2.0% · above model
ANAB
ANAPTYSBIO, INC
Fairly valued
Healthcare Risk 49 · Elevated
Price$53.87
Model IV$47.56
P/IV1.17
Premium +13% Return to IV: -11.7%
Market implies -1.6%/yr vs model +38.8% · below model
ANGI
Angi Inc.
Fairly valued
Technology Risk 58 · Elevated
Price$4.99
Model IV$4.61
P/IV1.27
Premium +8% Return to IV: -7.7%
Market implies -1.5%/yr vs model +0.1% · in line
AOUT
American Outdoor Brands, Inc.
Overvalued
Consumer Cyclical Risk 55 · Elevated
Price$15.68
Model IV$7.91
P/IV1.28
Premium +98% Return to IV: -49.6%
Market implies +10.3%/yr vs model +2.0% · above model
ARDX
ARDELYX, INC.
Overvalued
Healthcare Risk 50 · Elevated
Price$3.58
Model IV$13.06
P/IV1.19
Discount 73% Return to IV: +264.8%
Market implies -21.3%/yr vs model +50.0% · below model
ARHS
Arhaus, Inc.
Overvalued
Consumer Cyclical Risk 60 · High
Price$8.10
Model IV$5.99
P/IV1.28
Premium +35% Return to IV: -26.1%
Market implies +13.8%/yr vs model +12.7% · in line
AROW
ARROW FINANCIAL CORP
Overvalued
Financial Services Risk 67 · High
Price$39.15
Model IV$28.33
P/IV1.30
Premium +38% Return to IV: -27.6%
ASO
Academy Sports & Outdoors, Inc.
Overvalued
Consumer Cyclical Risk 64 · High
Price$55.36
Model IV$41.75
P/IV1.26
Premium +33% Return to IV: -24.6%
Market implies +9.8%/yr vs model +7.0% · in line
ATAT
Atour Lifestyle Holdings Ltd
Overvalued
Consumer Cyclical Risk 54 · Elevated
Price$32.41
Model IV$26.78
P/IV1.28
Premium +21% Return to IV: -17.4%
Market implies +21.5%/yr vs model +25.0% · below model
AUB
Atlantic Union Bankshares Corp
Overvalued
Financial Services Risk 49 · Elevated
Price$39.72
Model IV$32.49
P/IV1.16
Premium +22% Return to IV: -18.2%
AUBN
AUBURN NATIONAL BANCORPORATION, INC
Overvalued
Financial Services Risk 42 · Elevated
Price$26.54
Model IV$21.13
P/IV1.18
Premium +26% Return to IV: -20.4%
AVTR
Avantor, Inc.
Deeply overvalued
Healthcare Risk 46 · Elevated
Price$14.81
Model IV$7.83
P/IV1.16
Premium +89% Return to IV: -47.1%
Market implies +11.6%/yr vs model +3.0% · above model
AX
Axos Financial, Inc.
Overvalued
Financial Services Risk 61 · High
Price$93.75
Model IV$73.46
P/IV1.18
Premium +28% Return to IV: -21.6%
AXTA
Axalta Coating Systems Ltd.
Overvalued
Basic Materials Risk 49 · Elevated
Price$33.29
Model IV$26.35
P/IV1.17
Premium +26% Return to IV: -20.8%
Market implies +6.8%/yr vs model +4.1% · in line
BANC
BANC OF CALIFORNIA, INC.
Overvalued
Financial Services Risk 54 · Elevated
Price$18.55
Model IV$16.71
P/IV1.15
Premium +11% Return to IV: -9.9%
BANF
BANCFIRST CORP /OK/
Overvalued
Financial Services Risk 67 · High
Price$110.90
Model IV$88.21
P/IV1.25
Premium +26% Return to IV: -20.5%
BATRK
Atlanta Braves Holdings, Inc.
Overvalued
Communication Services Risk 54 · Elevated
Price$49.91
Model IV$39.47
P/IV1.26
Premium +26% Return to IV: -20.9%
Market implies -4.3%/yr vs model +7.6% · below model
BC
BRUNSWICK CORP
Overvalued
Industrials Risk 44 · Elevated
Price$70.72
Model IV$71.16
P/IV1.18
Discount 1% Return to IV: +0.6%
Market implies +5.7%/yr vs model +7.0% · in line
BCML
BayCom Corp
Overvalued
Financial Services Risk 52 · Elevated
Price$30.44
Model IV$26.28
P/IV1.17
Premium +16% Return to IV: -13.7%
BCSF
Bain Capital Specialty Finance, Inc.
Fairly valued
Unknown Risk 70 · High
Price$11.07
Model IV$10.95
P/IV1.22
Premium +1% Return to IV: -1.1%
Market implies -4.5%/yr vs model -1.6% · in line
BGLC
BioNexus Gene Lab Corp
Undervalued
Healthcare Risk 50 · Elevated
Price$1.44
Model IV$1.85
P/IV1.25
Discount 22% Return to IV: +28.6%
Market implies -10.9%/yr vs model +2.0% · below model
BHRB
Burke & Herbert Financial Services Corp.
Deeply overvalued
Financial Services Risk 52 · Elevated
Price$71.56
Model IV$53.36
P/IV1.19
Premium +34% Return to IV: -25.4%
BILL
BILL Holdings, Inc.
Overvalued
Technology Risk 56 · Elevated
Price$47.25
Model IV$29.00
P/IV1.28
Premium +63% Return to IV: -38.6%
Market implies +26.4%/yr vs model +25.0% · in line
BIO
BIO-RAD LABORATORIES, INC.
Overvalued
Healthcare Risk 54 · Elevated
Price$369.32
Model IV$254.24
P/IV1.23
Premium +45% Return to IV: -31.2%
Market implies +9.4%/yr vs model +5.5% · above model
BKU
BankUnited, Inc.
Overvalued
Financial Services Risk 56 · Elevated
Price$44.78
Model IV$36.84
P/IV1.26
Premium +22% Return to IV: -17.7%
BLLN
BillionToOne, Inc.
Overvalued
Healthcare Risk 49 · Elevated
Price$98.77
Model IV$83.33
P/IV1.19
Premium +19% Return to IV: -15.6%
Market implies +4.4%/yr vs model +50.0% · below model
BOKF
BOK FINANCIAL CORP
Overvalued
Financial Services Risk 56 · Elevated
Price$135.69
Model IV$103.78
P/IV1.23
Premium +31% Return to IV: -23.5%
BOX
BOX INC
Deeply overvalued
Technology Risk 51 · Elevated
Price$34.80
Model IV$22.48
P/IV1.20
Premium +55% Return to IV: -35.4%
Market implies +13.9%/yr vs model +10.1% · above model
BRC
BRADY CORP
Fairly valued
Consumer Cyclical Risk 46 · Elevated
Price$86.44
Model IV$76.09
P/IV1.19
Premium +14% Return to IV: -12.0%
Market implies +7.4%/yr vs model +6.8% · in line
BSET
BASSETT FURNITURE INDUSTRIES INC
Deeply overvalued
Consumer Cyclical Risk 53 · Elevated
Price$17.69
Model IV$12.38
P/IV1.21
Premium +43% Return to IV: -30.0%
Market implies +3.6%/yr vs model +1.3% · in line
BSRR
SIERRA BANCORP
Deeply overvalued
Financial Services Risk 68 · High
Price$40.84
Model IV$30.00
P/IV1.27
Premium +36% Return to IV: -26.5%
BURL
Burlington Stores, Inc.
Overvalued
Consumer Cyclical Risk 58 · Elevated
Price$239.04
Model IV$220.23
P/IV1.19
Premium +9% Return to IV: -7.9%
Market implies -1.3%/yr vs model +5.5% · below model
BVS
Bioventus Inc.
Deeply overvalued
Healthcare Risk 54 · Elevated
Price$13.16
Model IV$7.13
P/IV1.19
Premium +84% Return to IV: -45.8%
Market implies +13.9%/yr vs model +8.0% · above model
BWMN
Bowman Consulting Group Ltd.
Overvalued
Industrials Risk 56 · Elevated
Price$42.42
Model IV$24.76
P/IV1.27
Premium +71% Return to IV: -41.6%
Market implies +26.0%/yr vs model +25.0% · in line
CAC
CAMDEN NATIONAL CORP
Overvalued
Financial Services Risk 62 · High
Price$57.94
Model IV$40.01
P/IV1.25
Premium +45% Return to IV: -30.9%
CAKE
CHEESECAKE FACTORY INC
Deeply overvalued
Consumer Cyclical Risk 50 · Elevated
Price$102.70
Model IV$51.46
P/IV1.28
Premium +100% Return to IV: -49.9%
Market implies +16.7%/yr vs model +9.0% · above model
CBNA
CHAIN BRIDGE BANCORP INC
Overvalued
Financial Services Risk 55 · Elevated
Price$46.32
Model IV$30.60
P/IV1.18
Premium +51% Return to IV: -33.9%
CCBG
CAPITAL CITY BANK GROUP INC
Overvalued
Financial Services Risk 46 · Elevated
Price$50.70
Model IV$38.35
P/IV1.19
Premium +32% Return to IV: -24.4%
CHCO
CITY HOLDING CO
Overvalued
Financial Services Risk 62 · High
Price$143.96
Model IV$100.56
P/IV1.24
Premium +43% Return to IV: -30.1%
CIMN
CHIMERA INVESTMENT CORP
Overvalued
Financial Services Risk 53 · Elevated
Price$25.07
Model IV$21.56
P/IV1.17
Premium +16% Return to IV: -14.0%
CIMO
CHIMERA INVESTMENT CORP
Overvalued
Financial Services Risk 57 · Elevated
Price$25.28
Model IV$21.56
P/IV1.17
Premium +17% Return to IV: -14.7%
CIMP
CHIMERA INVESTMENT CORP
Overvalued
Financial Services Risk 58 · Elevated
Price$25.07
Model IV$21.56
P/IV1.16
Premium +16% Return to IV: -14.0%
CLAR
Clarus Corp
Overvalued
Consumer Cyclical Risk 55 · Elevated
Price$3.55
Model IV$2.36
P/IV1.30
Premium +50% Return to IV: -33.4%
Market implies +5.7%/yr vs model +2.0% · above model
CLIR
ClearSign Technologies Corp
Fairly valued
Healthcare Risk 45 · Elevated
Price$3.85
Model IV$3.84
P/IV1.21
Premium +0% Return to IV: -0.3%
Market implies -2.6%/yr vs model +50.0% · below model
CLST
Catalyst Bancorp, Inc.
Overvalued
Financial Services Risk 60 · High
Price$18.05
Model IV$12.29
P/IV1.30
Premium +47% Return to IV: -31.9%
CMTV
COMMUNITY BANCORP /VT
Overvalued
Financial Services Risk 55 · Elevated
Price$40.49
Model IV$31.37
P/IV1.15
Premium +29% Return to IV: -22.5%
CNDT
CONDUENT Inc
Valuation N/A
Technology Risk 61 · High
Price$1.57
Model IV
P/IV
Market implies -1.8%/yr vs model +0.0% · in line
COLM
COLUMBIA SPORTSWEAR CO
Fairly valued
Consumer Cyclical Risk 54 · Elevated
Price$57.67
Model IV$57.19
P/IV1.16
Premium +1% Return to IV: -0.8%
Market implies +6.8%/yr vs model +7.9% · in line
CPBI
Central Plains Bancshares, Inc.
Overvalued
Financial Services Risk 56 · Elevated
Price$21.40
Model IV$14.16
P/IV1.30
Premium +51% Return to IV: -33.8%
CPIX
CUMBERLAND PHARMACEUTICALS INC
Overvalued
Healthcare Risk 60 · High
Price$6.39
Model IV$5.02
P/IV1.22
Premium +27% Return to IV: -21.4%
Market implies +7.0%/yr vs model +7.3% · in line
CRON
Cronos Group Inc.
Overvalued
Healthcare Risk 42 · Elevated
Price$3.14
Model IV$2.46
P/IV1.15
Premium +27% Return to IV: -21.5%
Market implies -6.6%/yr vs model +22.8% · below model
CTBI
COMMUNITY TRUST BANCORP INC /KY/
Overvalued
Financial Services Risk 52 · Elevated
Price$77.67
Model IV$56.24
P/IV1.19
Premium +38% Return to IV: -27.6%